A recent study suggests that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds far faster than those who stop traditional lifestyle plans.
Findings released in a prominent health publication shows that while overweight individuals can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals using these drugs must be aware of the risk of quick rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
That rate of regain means a return to original mass within about a year and a half.
Comparing Approaches
The study, which reviewed 37 of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
Researchers emphasize that people who shed pounds through dieting typically see a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Nutrition scientists propose the mechanism of the drugs explains the amplified regain.
These medications mimic a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of GLP-1 levels far above than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication results in appetite is uncontrolled, making binge eating much more probable."
A Lifelong Issue?
Medical guidelines advise the injections for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, given the likelihood of relapse, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who say that the results "highlight the long-term nature of obesity," comparing it to managing conditions like diabetes.
Patient Accounts
People who have come off the medication report a sudden resurgence of hunger.
"I experienced a trigger that goes on and I was suddenly extremely hungry," recalled an individual.
The struggle is worsened if individuals have not established permanent lifestyle or habit modifications during therapy.
Widespread Use
Figures show that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is more common among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, experts caution that while the jabs are potent agents for shedding pounds, they are not a magic fix and lasting health benefits hinges on combined lifestyle management.
